Johnson & Johnson (NYSE:JNJ) Shares Sold by Moody National Bank Trust Division

Moody National Bank Trust Division decreased its position in Johnson & Johnson (NYSE:JNJFree Report) by 41.2% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 37,308 shares of the company’s stock after selling 26,168 shares during the quarter. Johnson & Johnson accounts for about 0.5% of Moody National Bank Trust Division’s holdings, making the stock its 22nd biggest holding. Moody National Bank Trust Division’s holdings in Johnson & Johnson were worth $5,848,000 at the end of the most recent reporting period.

Other hedge funds have also recently added to or reduced their stakes in the company. RPG Investment Advisory LLC raised its stake in Johnson & Johnson by 1.2% in the second quarter. RPG Investment Advisory LLC now owns 4,876 shares of the company’s stock valued at $807,000 after buying an additional 60 shares during the period. FIDELIS iM LLC increased its stake in shares of Johnson & Johnson by 3.1% during the fourth quarter. FIDELIS iM LLC now owns 2,117 shares of the company’s stock worth $374,000 after purchasing an additional 64 shares during the period. TFG Advisers LLC increased its stake in shares of Johnson & Johnson by 0.4% during the third quarter. TFG Advisers LLC now owns 18,330 shares of the company’s stock worth $2,855,000 after purchasing an additional 67 shares during the period. Kellett Wealth Advisors LLC increased its stake in shares of Johnson & Johnson by 3.8% during the third quarter. Kellett Wealth Advisors LLC now owns 1,880 shares of the company’s stock worth $293,000 after purchasing an additional 68 shares during the period. Finally, Hutchinson Capital Management CA increased its stake in shares of Johnson & Johnson by 0.6% during the third quarter. Hutchinson Capital Management CA now owns 10,566 shares of the company’s stock worth $1,646,000 after purchasing an additional 68 shares during the period. Institutional investors and hedge funds own 68.40% of the company’s stock.

Insider Activity at Johnson & Johnson

In other Johnson & Johnson news, EVP Jennifer L. Taubert sold 59,397 shares of Johnson & Johnson stock in a transaction dated Friday, February 9th. The stock was sold at an average price of $156.27, for a total transaction of $9,281,969.19. Following the completion of the transaction, the executive vice president now owns 141,416 shares in the company, valued at approximately $22,099,078.32. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In other news, major shareholder & Johnson Johnson sold 3,725 shares of the business’s stock in a transaction that occurred on Friday, February 16th. The stock was sold at an average price of $25.81, for a total value of $96,142.25. Following the transaction, the insider now owns 4,099,575 shares in the company, valued at approximately $105,810,030.75. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, EVP Jennifer L. Taubert sold 59,397 shares of the business’s stock in a transaction that occurred on Friday, February 9th. The stock was sold at an average price of $156.27, for a total value of $9,281,969.19. Following the completion of the transaction, the executive vice president now owns 141,416 shares in the company, valued at approximately $22,099,078.32. The disclosure for this sale can be found here. 0.20% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

A number of research firms have commented on JNJ. Raymond James raised their price objective on Johnson & Johnson from $172.00 to $175.00 and gave the stock an “outperform” rating in a research note on Wednesday, January 3rd. Morgan Stanley reduced their target price on Johnson & Johnson from $170.00 to $169.00 and set an “equal weight” rating on the stock in a report on Wednesday, January 24th. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $181.00 target price on shares of Johnson & Johnson in a report on Wednesday, February 28th. Wells Fargo & Company downgraded Johnson & Johnson from an “overweight” rating to an “equal weight” rating and reduced their target price for the company from $170.00 to $163.00 in a report on Wednesday, December 13th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $215.00 target price on shares of Johnson & Johnson in a report on Wednesday, March 13th. Seven investment analysts have rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $177.31.

Get Our Latest Stock Analysis on JNJ

Johnson & Johnson Stock Performance

JNJ stock opened at $155.71 on Friday. The stock has a 50-day moving average price of $159.25 and a 200-day moving average price of $156.83. Johnson & Johnson has a 1-year low of $144.95 and a 1-year high of $175.97. The company has a current ratio of 1.16, a quick ratio of 0.91 and a debt-to-equity ratio of 0.38. The firm has a market cap of $375.23 billion, a PE ratio of 11.28, a price-to-earnings-growth ratio of 2.62 and a beta of 0.53.

Johnson & Johnson (NYSE:JNJGet Free Report) last posted its quarterly earnings data on Tuesday, January 23rd. The company reported $2.29 earnings per share for the quarter, topping the consensus estimate of $2.28 by $0.01. Johnson & Johnson had a return on equity of 37.27% and a net margin of 37.79%. The firm had revenue of $21.40 billion during the quarter, compared to analyst estimates of $21.02 billion. During the same period last year, the company posted $2.35 EPS. The business’s quarterly revenue was down 9.7% on a year-over-year basis. As a group, equities research analysts expect that Johnson & Johnson will post 10.65 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Tuesday, March 5th. Investors of record on Tuesday, February 20th were given a $1.19 dividend. This represents a $4.76 dividend on an annualized basis and a yield of 3.06%. The ex-dividend date was Friday, February 16th. Johnson & Johnson’s payout ratio is 34.47%.

Johnson & Johnson Company Profile

(Free Report)

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.

Featured Articles

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJFree Report).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.